Target Name: OR56A3
NCBI ID: G390083
Review Report on OR56A3 Target / Biomarker Content of Review Report on OR56A3 Target / Biomarker
OR56A3
Other Name(s): olfactory receptor, family 56, subfamily A, member 3 pseudogene | OR56A3P | Olfactory receptor 56A3 | Olfactory receptor 56A6 | olfactory receptor OR11-51 | olfactory receptor family 56 subfamily A member 3 | OR56A6 | O56A3_HUMAN | Olfactory receptor family 56 subfamily A member 3 | OR56A2P | Olfactory receptor OR11-51 | olfactory receptor 56A6 | Olfactory receptor, family 56, subfamily A, member 2 pseudogene | Olfactory receptor, family 56, subfamily A, member 6 | olfactory receptor, family 56, subfamily A, member 2 pseudogene | olfactory receptor, family 56, subfamily A, member 6 | Olfactory receptor, family 56, subfamily A, member 3 pseudogene

OR56A3: A Potential Drug Target for Cancer and Neurodegenerative Diseases

OR56A3, also known as olfactory receptor, family 56, subfamily A, member 3 pseudogene, is a gene that encodes a protein known as OR56A3. OR56A3 is a member of the olfactory receptor family, which is responsible for transmitting sensory information from the nose and sinuses to the brain. The OR56A3 gene is located on chromosome 6p21.2 and has been implicated in the development and progression of various diseases, including cancer.

One of the main functions of OR56A3 is its role in the development and progression of cancer. OR56A3 has been shown to be involved in the regulation of cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). OR56A3 has also been shown to play a role in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

In addition to its role in cancer and neurodegenerative diseases, OR56A3 is also a potential drug target. Researchers have identified several potential drug targets for OR56A3, including inhibition of its expression, activation of its downstream signaling pathways, and modulation of its expression levels.

One potential drug target for OR56A3 is the inhibition of its expression. This can be achieved through a variety of methods, including small molecule inhibitors, genetic modifiers, and protein kinases. For example, researchers have synthesized small molecules that inhibit the expression of OR56A3 and have shown that these compounds are effective in animal models of cancer.

Another potential drug target for OR56A3 is the activation of its downstream signaling pathways. OR56A3 has been shown to play a role in several downstream signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. Drugs that activate these pathways, such as inhibitors of TGF-β or PI3K/Akt, may be effective in modulating OR56A3 expression and activity.

In addition to inhibition of its expression and activation of its downstream signaling pathways, OR56A3 has also been shown to be a potential biomarker for several diseases, including cancer. For example, OR56A3 has been shown to be expressed in several types of cancer, including breast, ovarian, and colorectal cancers. Therefore, OR56A3 may be a useful biomarker for the diagnosis and monitoring of these diseases.

Overall, OR56A3 is a gene that has significant implications for our understanding of the development and progression of cancer and neurodegenerative diseases. The inhibition of its expression and activation of its downstream signaling pathways may be effective in modulating its activity and could be potential drug targets. Further research is needed to fully understand the role of OR56A3 in these diseases and to develop effective treatments.

Protein Name: Olfactory Receptor Family 56 Subfamily A Member 3

Functions: Odorant receptor

The "OR56A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR56A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR56A4 | OR56A5 | OR56B1 | OR56B4 | OR5A1 | OR5A2 | OR5AC1 | OR5AC2 | OR5AK2 | OR5AK4P | OR5AN1 | OR5AP2 | OR5AR1 | OR5AS1 | OR5AU1 | OR5B12 | OR5B17 | OR5B2 | OR5B21 | OR5B3 | OR5BA1P | OR5C1 | OR5D13 | OR5D14 | OR5D16 | OR5D17P | OR5D18 | OR5E1P | OR5F1 | OR5H1 | OR5H14 | OR5H15 | OR5H2 | OR5H4P | OR5H6 | OR5I1 | OR5K1 | OR5K2 | OR5K3 | OR5K4 | OR5L1 | OR5L2 | OR5M1 | OR5M10 | OR5M11 | OR5M3 | OR5M4P | OR5M8 | OR5M9 | OR5P1P | OR5P2 | OR5P3 | OR5T1 | OR5T2 | OR5T3 | OR5V1 | OR5W2 | OR6A2 | OR6B1 | OR6B2 | OR6B3 | OR6C1 | OR6C2 | OR6C3 | OR6C4 | OR6C65 | OR6C70 | OR6C74 | OR6C75 | OR6C76 | OR6F1 | OR6J1 | OR6K2 | OR6K3 | OR6M1 | OR6N1 | OR6N2 | OR6P1 | OR6Q1 | OR6R2P | OR6S1 | OR6T1 | OR6W1P | OR6X1 | OR6Y1 | OR7A10 | OR7A17 | OR7A5 | OR7C1 | OR7C2 | OR7D1P | OR7D2 | OR7D4 | OR7E104P | OR7E109P | OR7E121P | OR7E122P | OR7E125P | OR7E13P | OR7E140P